Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
55% OFF
PC:NEU2B

Neurolixis

Windsor Dr Park Ridge, New Jersey 07656, UShttps://www.neurolixis.com/Therapeutics

Neurolixis is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapeutics for neurological and neuropsychiatric disorders. The company advances a pipeline of compounds designed to modulate neurotransmitter systems with the goal of improving motor, cognitive, and behavioral symptoms, and engages in preclinical research, clinical development, and strategic collaborations to progress its programs.

Leadership & Board

Current Number of Employees
5
Current LinkedIn Followers
1,713

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$15K
Total Funding Rounds
1
Latest Funding Amount
$15K
Latest Funding Round
Seed Round
Post-Money Valuation
―

Employee Trend

Neurolixis had 5 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.

5Latest Employee Count
0(0.00%)Week-Over-Week Change
02468Feb 16, 2026Mar 02, 2026Mar 16, 2026Mar 30, 2026Apr 13, 2026May 04, 2026May 18, 2026Jun 01, 2026Jun 15, 2026Jun 29, 2026Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026

Social Trend

Neurolixis had 1,713 followers as of October 12, 2026. The number of followers increased by 0 (0.00%) week-over-week.

1,713Latest Followers Count
0(0.00%)Week-Over-Week Change
05001,0001,5002,000Feb 16, 2026Mar 02, 2026Mar 16, 2026Mar 30, 2026Apr 13, 2026May 04, 2026May 18, 2026Jun 01, 2026Jun 15, 2026Jun 29, 2026Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Aug 18, 2013Seed Round$15.00K―

Similar Companies

A snapshot of private companies similar to Neurolixis, helping you discover and navigate related company profiles.

PC:SPI60Spiral TherapeuticsPC:ORTHOOrthopedic Care PartnersPC:ACCIPAccipiter BiosciencesPC:ANGIEAngiex Inc

Related News and Analysis

Preclinical Data Highlight Disease-Modifying Potential of Neurolixis Parkinson’s Candidate

Preclinical Data Highlight Disease-Modifying Potential of Neurolixis Parkinson’s Candidate

According to a recent LinkedIn post from Neurolixis, new preclinical data from the University of Hertfordshire suggest that NLX-112 (befiradol), a selective 5-HT1A receptor agonist, may have disease-modifying potential in
3M ago
NEU2B
Neurolixis – Weekly Recap

Neurolixis – Weekly Recap

Neurolixis is a privately held neuropharmaceutical company advancing novel therapies for movement disorders, and this weekly summary reviews its latest update on lead candidate NLX-112. During the week, the company
6M ago
NEU2B
Neurolixis Highlights NLX-112 Data and Signals Openness to Investment or Licensing

Neurolixis Highlights NLX-112 Data and Signals Openness to Investment or Licensing

According to a recent LinkedIn post from Neurolixis, the company is drawing attention to a new academic publication from Northwestern University that investigates 5-HT1 receptor activation using phMRI in mice.
6M ago
NEU2B
Neurolixis Highlights NLX-112 Data and Signals Openness to Investment and Licensing

Neurolixis Highlights NLX-112 Data and Signals Openness to Investment and Licensing

According to a recent LinkedIn post from Neurolixis, the company is drawing attention to a new academic publication from Northwestern University that investigated 5-HT1 receptor activation using phMRI in mice.
6M ago
NEU2B
Neurolixis Highlights Orphan-Designated Fragile X Candidate NLX-101 and Seeks Development Partner

Neurolixis Highlights Orphan-Designated Fragile X Candidate NLX-101 and Seeks Development Partner

According to a recent LinkedIn post from Neurolixis, new peer‑reviewed preclinical data suggest its investigational compound NLX‑101 may address multiple behavioral deficits in a validated Fragile X syndrome mouse model.
7M ago
NEU2B
Neurolixis Highlights Orphan-Designated NLX-101 Preclinical Data in Fragile X Syndrome

Neurolixis Highlights Orphan-Designated NLX-101 Preclinical Data in Fragile X Syndrome

According to a recent LinkedIn post from Neurolixis, peer-reviewed preclinical data suggest that its investigational compound NLX-101 improved a broad range of behavioral deficits in a validated Fragile X Syndrome
7M ago
NEU2B
Dominion Dynamics to Build AuraNet-Enabled Combat UGVs in Canada for Ukraine and NATO

Dominion Dynamics to Build AuraNet-Enabled Combat UGVs in Canada for Ukraine and NATO

New updates have been reported about Dominion Dynamics. Dominion Dynamics has signed a memorandum of understanding with Ukrainian defence firm TENCORE to manufacture TENCORE’s TerMIT uncrewed ground vehicles in Canada
53m ago
DOMIN
Mogul Raises $15.5 Million Series A to Scale AI-Driven Real Estate Platform

Mogul Raises $15.5 Million Series A to Scale AI-Driven Real Estate Platform

New updates have been reported about Mogul. Mogul has closed an oversubscribed $15.5 million Series A round led by Draper Associates, lifting its valuation to $126 million and bringing total
2h ago
MOGUL
Arch Lending Backs Community Bitcoin Reserve Model in Chicago’s Altgeld Gardens

Arch Lending Backs Community Bitcoin Reserve Model in Chicago’s Altgeld Gardens

New updates have been reported about Arch Lending. Arch Lending, the U.S.-based alternative-asset lending platform operated by ChainFi, Inc., has become a founding private-sector supporter of the Altgeld Bitcoin Reserve
3h ago
ARCHL
Lantern Launches Glo, an AI-Native Platform to Run Staffing Operations

Lantern Launches Glo, an AI-Native Platform to Run Staffing Operations

New updates have been reported about Lantern. Lantern has introduced Glo, an AI-native staffing and recruiting platform positioned as a full replacement for traditional applicant tracking and CRM systems, debuting
4h ago
LANTE